CY1116968T1 - Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια - Google Patents

Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια

Info

Publication number
CY1116968T1
CY1116968T1 CY20151101069T CY151101069T CY1116968T1 CY 1116968 T1 CY1116968 T1 CY 1116968T1 CY 20151101069 T CY20151101069 T CY 20151101069T CY 151101069 T CY151101069 T CY 151101069T CY 1116968 T1 CY1116968 T1 CY 1116968T1
Authority
CY
Cyprus
Prior art keywords
painylamin
active substance
packaging containing
nrc
preparation
Prior art date
Application number
CY20151101069T
Other languages
English (en)
Inventor
Durga Maheswari Parvataneni
Siddhartha Yedluri
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116968(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of CY1116968T1 publication Critical patent/CY1116968T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Ένα φαρμακευτικό σκεύασμα για λήψη από του στόματος το οποίο περιέχει μια αποτελεσματική ποσότητα NRC-AN-019 συμπεριλαμβανομένων των φαρμακευτικά αποδεκτών αλάτων και πολυμόρφων του, όπως Μορφή I, Μορφή II και Μορφή III, για τη βελτίωση της βιοδιαθεσιμότητας και προορίζεται για αυτο-γαλακτωματοποίηση κατά την επαφή του με το γαστρεντερικό υγρό. Η εφεύρεση σχετίζεται επίσης με μια διαδικασία για την παρασκευή στοματικού διαλύματος που περιέχει το NRC-AN-019 σε αποτελεσματική συγκέντρωση για την καλύτερη θεραπεία της Χρόνιας Μυελογενούς Λευχαιμίας ως αναστολέας της τυροσινικής κινάσης BCR-ABL και για τη θεραπεία άλλων όγκων, όπως καρκίνος της κεφαλής και του λαιμού, καρκίνος του προστάτη και τα συναφή.
CY20151101069T 2011-03-07 2015-11-26 Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια CY1116968T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
EP11764851.9A EP2683381B1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
CY1116968T1 true CY1116968T1 (el) 2017-04-05

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151101069T CY1116968T1 (el) 2011-03-07 2015-11-26 Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια

Country Status (32)

Country Link
US (1) US9895367B2 (el)
EP (1) EP2683381B1 (el)
JP (1) JP5788534B2 (el)
KR (1) KR101767296B1 (el)
CN (1) CN103561742B (el)
AP (1) AP4076A (el)
AU (1) AU2011361921B2 (el)
BR (1) BR112013022930A2 (el)
CA (1) CA2829015C (el)
CO (1) CO6811851A2 (el)
CY (1) CY1116968T1 (el)
DK (1) DK2683381T3 (el)
EA (1) EA024610B1 (el)
ES (1) ES2554927T3 (el)
GB (1) GB2488788B (el)
GE (1) GEP20156410B (el)
HR (1) HRP20151382T1 (el)
HU (1) HUE025562T2 (el)
IL (1) IL228218A (el)
MA (1) MA35088B1 (el)
MX (1) MX339130B (el)
MY (1) MY158693A (el)
NZ (1) NZ614903A (el)
PL (1) PL2683381T3 (el)
PT (1) PT2683381E (el)
RS (1) RS54420B1 (el)
SG (1) SG193349A1 (el)
SI (1) SI2683381T1 (el)
SM (1) SMT201500235B (el)
UA (1) UA111074C2 (el)
WO (1) WO2012120328A1 (el)
ZA (1) ZA201306643B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211590T1 (hr) 2015-12-18 2022-01-07 Natco Pharma Ltd Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina
EP3397242B1 (en) * 2015-12-29 2021-02-03 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
LT3765024T (lt) * 2018-03-14 2024-02-26 KaNDy Therapeutics Limited Nauja farmacinė vaisto forma, apimanti dvigubo nk-1/nk-3 receptoriaus antagonistus
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU728698B2 (en) * 1997-07-29 2001-01-18 Boehringer Ingelheim International Gmbh Self-emulsifying formulation for lipophilic compounds
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
JP5184887B2 (ja) 2004-09-09 2013-04-17 ナトコ ファーマ リミテッド ｂｃｒ−ａｂｌキナーゼの阻害剤としての新規フェニルアミノピリミジン誘導体
US20080207904A1 (en) * 2006-10-26 2008-08-28 Macdonald Peter Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
ES2357354T3 (es) * 2007-04-30 2011-04-25 Intezyne Technologies Inc. Micelas híbridas de copolímero en bloque con estereoquímica mixta para encapsulación de agentes hidrófobos.
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
MX2010009401A (es) 2008-03-04 2010-09-24 Natco Pharma Ltd Forma cristalina de derivado de fenilamino pirimidina.
AU2009325091A1 (en) * 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor

Also Published As

Publication number Publication date
AP2013007128A0 (en) 2013-09-30
PL2683381T3 (pl) 2016-06-30
CA2829015A1 (en) 2012-09-13
SI2683381T1 (sl) 2016-01-29
JP5788534B2 (ja) 2015-09-30
ES2554927T3 (es) 2015-12-28
MA35088B1 (fr) 2014-05-02
MY158693A (en) 2016-11-15
JP2014507463A (ja) 2014-03-27
CN103561742A (zh) 2014-02-05
SG193349A1 (en) 2013-10-30
KR20140016926A (ko) 2014-02-10
GB2488788A (en) 2012-09-12
EP2683381A1 (en) 2014-01-15
AU2011361921B2 (en) 2016-06-09
US20130338180A1 (en) 2013-12-19
AP4076A (en) 2017-03-23
SMT201500235B (it) 2015-10-30
RS54420B1 (en) 2016-04-28
CA2829015C (en) 2018-01-02
GEP20156410B (en) 2015-12-10
UA111074C2 (uk) 2016-03-25
EA201391280A1 (ru) 2014-02-28
CO6811851A2 (es) 2013-12-16
MX2013010160A (es) 2013-12-06
ZA201306643B (en) 2014-11-26
PT2683381E (pt) 2015-11-02
HRP20151382T1 (hr) 2016-02-12
NZ614903A (en) 2014-08-29
HUE025562T2 (en) 2016-03-29
EP2683381B1 (en) 2015-09-16
GB201103860D0 (en) 2011-04-20
AU2011361921A2 (en) 2014-10-30
AU2011361921A1 (en) 2013-09-26
WO2012120328A1 (en) 2012-09-13
KR101767296B1 (ko) 2017-08-10
BR112013022930A2 (pt) 2016-12-06
DK2683381T3 (en) 2015-12-21
CN103561742B (zh) 2016-04-27
US9895367B2 (en) 2018-02-20
GB2488788B (en) 2013-07-10
MX339130B (es) 2016-05-13
EA024610B1 (ru) 2016-10-31
IL228218A (en) 2016-06-30

Similar Documents

Publication Publication Date Title
CY1116968T1 (el) Σκευασμα που περιεχει παραγωγο φαινυλαμινοπυριμιδινης ως δραστικη ουσια
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
CY1122611T1 (el) Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης
CY1119090T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
CY1121416T1 (el) Yποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων
CY1125613T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1119676T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1116231T1 (el) ΑΛΑΤΑ ΥΠΟΚΑΤΕΣΤΗΜΕΝΗΣ 2,3-ΔIYΔPOΪMIΔAZO[l,2-C] ΚΙΝΑΖΟΛΙΝΗΣ
CY1119227T1 (el) Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
MX2009013835A (es) Forma de dosis estabilizada de picoplatino.
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
CY1121089T1 (el) Χρηση των παραγωγων της βενζιμιδαζολης-προλινης
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201591024A1 (ru) Димерные соединения
CY1124580T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν παραγωγα φαινυλαμινοπυριμιδινης
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.